Lv1
80 积分 2025-06-16 加入
Phase 1/2 Trial of Anti-CD7 Allogeneic WU-CART-007 in patients with Relapsed/Refractory T-cell Malignancies
5天前
已关闭
WU-CART-007, an Allogeneic CAR T-Cell Targeting CD7 in Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL): Phase 2 Results
5天前
已完结
Phase 1/2 Trial of Anti-CD7 Allogeneic WU-CART-007 in patients with Relapsed/Refractory T-cell Malignancies
6天前
已完结
E3 ligase RAD18 targets phosphorylated IRF3 to terminate IFNB1 transcription
23天前
已完结
Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial
1个月前
已完结
The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment
1个月前
已完结
Oncologic outcomes and trends in each colon cancer location and stages over the last two decades: insights from the SEER registry
1个月前
已完结
Oncologic outcomes and trends in each colon cancer location and stages over the last two decades: insights from the SEER registry
2个月前
已完结
Best Practices and Considerations for Clinical Pharmacology and Pharmacometric Aspects for Optimal Development of CAR-T and TCR-T Cell Therapies: An Industry Perspective
3个月前
已完结
皖公网安备34019202002308
